BioVersys Receives Funding to Develop Antimicrobial Therapies

November 1, 2019

Swiss-based company, BioVersys, has been granted funding worth up to $8.92 million by CARB-X to support the development of anti-virulence small molecule drugs that disarm bacteria, which could offer a paradigm shift in antimicrobial resistance (AMR) therapy.

Swiss-based company, BioVersys, has been granted funding worth up to $8.92 million by CARB-X to support the development of anti-virulence small molecule drugs that disarm bacteria, which could offer a paradigm shift in antimicrobial resistance (AMR) therapy. 

“We are delighted that CARB-X recognizes the immense potential of BioVersys’ anti-virulence program (BV200) through this funding award,” said Dr. Marc Gitzinger, CEO and co-founder of BioVersys in an Oct. 29, 2019 press release. “The diversity in the challenge of AMR diseases, requires us to broaden our approach beyond classical antibiotics, and further R&D investment in novel paradigm shifting approaches such as anti-virulence is vitally important. BioVersys is committed to continue its development of novel targeted antimicrobials and deliver new treatment options to AMR patients worldwide.”

Dr. Seng Chin Mah, chairman of BioVersys, added, “BioVersys continues its innovative approach to generating high value medicines in the AMR space with an anti-virulence therapy. This CARB-X award is testimony to the fact that we not only need to develop new drugs but also to preserve existing ones. BV200 serves this dual purpose. We will continue to execute on our multi-asset corporate strategy to progress several much-needed therapies to clinical development in the coming years and eventually to patients with urgent unmet medical need. In doing so, we will also increase stakeholder value.”

The funding incorporates $3.94 million in non-dilutive funding and possibly $4.98 million more if specific milestones are met.

Source: CARB-X